Moderna Inc
NASDAQ: MRNA
$125.00
-$0.59 (-0.5%)
Closing price May 3, 2024
MRNA Articles
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Published:
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published:
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
Published:
Tuesday's top analyst upgrades and downgrades include Apple, Baidu, Boeing, Delta Air Lines, L3Harris Technologies, Moderna, Raytheon Technologies, Roku and Walt Disney.
Published:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
Independent research firm Argus has reiterated its Buy rating on Moderna and is calling this large pullback a buying opportunity.
Published:
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Published:
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
Published:
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Published:
Thursday's top analyst upgrades and downgrades included Apache, Check Point Software Technologies, Chipotle Mexican Grill, Electronic Arts, Inogen, Microsoft, Moderna, Shopify, Tesla and Varonis...
Published: